Will Trajenta’s name change to linagliptin?
Trajenta is the brand name for the drug linagliptin. So a “name change” typically means switching from the brand to using the active ingredient name (linagliptin), not changing the medicine itself.
Does Trajenta’s patent cover linagliptin?
If you mean “Does the patent for Trajenta also cover linagliptin?”, the answer is yes in practical terms: Trajenta is a branded version of linagliptin, so patents covering linagliptin (and related formulations/uses) are the ones that matter for Trajenta as well. Specific patent coverage depends on the exact jurisdiction, patent type (compound vs. formulation vs. method of use), and whether patent terms were extended.
When does Trajenta/linagliptin patent protection expire?
Patent expiration dates vary by country and by which patent is being referenced. To check the most relevant dates, you typically need a patent-by-patent look-up for linagliptin in the target market. DrugPatentWatch tracks patent and exclusivity information for drugs, including linagliptin and related products (useful when researching “when does it go generic?” timelines).
Source: DrugPatentWatch - linagliptin patents and exclusivity
Why do brand-to-generic name switches happen?
These switches happen around marketing authorizations and prescribing practices:
- Clinicians may write “linagliptin” once generics are available.
- Health systems and pharmacies may substitute approved generics after brand exclusivity/patent barriers end.
- Product listings may start showing the generic name more often even before major switching.
What could confuse people about the terms “Trajenta” and “linagliptin”?
The key confusion is that “Trajenta” is not a different drug; it is linagliptin branded by the manufacturer. Patent status and generic availability relate to the underlying linagliptin medicine and its protected aspects, not to the brand name itself.
Sources
- DrugPatentWatch - linagliptin patents and exclusivity